หน้าแรก
ค้นหา
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
No description available
แสดงข้อมูลเพิ่มเติม 1
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic ...
BIG BANG: binimetinib, encorafenib, and cetuximab in BRAF non-V600E mutated mCRC
Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC
BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRC
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal cancer
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC
First-Line Triplet in BRAF+ mCRC
Real-World Management of Patients with BRAF-V600E mCRC
Triplet Regimen Improves Responses in BRAF V600E+ Metastatic CRC
Encoranefib, Binimetinib, and Cetuximab in BRAF V600E mutated colorectal cancer
New Therapy Options for BRAF-Mutated mCRC
Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer
Encorafenib for BRAF-mutant Colorectal Cancer
Safety Lead-In Data for BEACON CRC Trial With Triplet Biologic Regimen in mCRC
Triplet Therapy for Certain Patients with Metastatic CRC Shows Promise, But More Research is Needed
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-m...
Colorectal Cancer Debate: First Line BRAF V600E - FOLFOXIRI/Bev
